Overview

Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF

Status:
Terminated
Trial end date:
2017-06-16
Target enrollment:
Participant gender:
Summary
The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals